

Title: Achieving Optimal Patient Outcomes in Renal Cell Carcinoma: Translating Evidence Into Clinical Practice

Dates: Live activities held January 14, 2016, January 27, 2016, February 4, 2016, February 16, 2016, February 25, 2016, March 2, 2016, March 16, 2016, March 18, 2016, March 22, 2016, and May 17, 2016

Locations: Cleveland, OH; Alexandria, VA; Lawrenceville, GA; Sylmar, CA; Asheville, NC; Chicago, IL; Middletown, CT; Washington, DC; West Palm Beach, FL; and Providence, RI

Learning Objectives

At the conclusion of this activity, participants should be better able to:

- Assess the efficacy and safety of currently approved agents for the treatment of metastatic renal cell carcinoma (RCC)
- Review treatment selection, sequencing of agents, and dosing strategies used in the treatment of RCC
- Explain how to integrate appropriate targeted therapy for patients with RCC based on tumor histology and risk stratification
- Discuss strategies to effectively manage side effects associated with RCC treatment
- Identify emerging therapies under investigation in clinical trials for the treatment of RCC

Target Audience

This activity is designed for medical oncologists, urologists, genitourinary oncologists, oncology nurses, and other healthcare professionals involved in the care and treatment of patients with advanced RCC.

Program Overview

This activity will address educational gaps related to the treatment and management of RCC and provide strategies to integrate FDA-approved agents into clinical practice to aid clinicians with the selection of optimal treatment.

Faculty

Brian I. Rini, MD, FACP (Chair)
Professor of Medicine
Lerner College of Medicine
Leader, GU Program
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Clinical and Patient Educators Association (CPEA) and AXIS Medical Education. CPEA is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation Statement

Clinical and Patient Educators Association designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credit*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest

CPEA requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by CPEA for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Commercial Support

This activity is supported by independent educational grants from Novartis Pharmaceuticals and Prometheus Laboratories Inc.